Turn Therapeutics (NASDAQ:TTRX) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Turn Therapeutics (NASDAQ:TTRX) to a hold rating in a report released on Tuesday,Zacks.com reports.

Several other research firms have also weighed in on TTRX. D. Boral Capital reiterated a “buy” rating and issued a $8.00 target price on shares of Turn Therapeutics in a report on Tuesday, March 24th. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a report on Monday. Weiss Ratings upgraded shares of Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. Finally, Wall Street Zen raised Turn Therapeutics to a “hold” rating in a research note on Saturday, July 18th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Turn Therapeutics Trading Down 5.5%

NASDAQ:TTRX opened at $9.62 on Tuesday. The company has a current ratio of 2.23, a quick ratio of 2.23 and a debt-to-equity ratio of 0.97. Turn Therapeutics has a 1-year low of $2.57 and a 1-year high of $26.50. The firm has a market capitalization of $286.58 million and a price-to-earnings ratio of -50.63. The business’s 50-day moving average price is $6.70 and its two-hundred day moving average price is $4.81.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.03) EPS for the quarter. On average, equities analysts expect that Turn Therapeutics will post -0.09 earnings per share for the current year.

Institutional Investors Weigh In On Turn Therapeutics

Several institutional investors have recently bought and sold shares of TTRX. XTX Topco Ltd acquired a new stake in shares of Turn Therapeutics in the fourth quarter valued at approximately $99,000. Millennium Management LLC bought a new position in Turn Therapeutics in the fourth quarter valued at $377,000. Jane Street Group LLC acquired a new stake in Turn Therapeutics in the 4th quarter valued at $68,000. Brown Brothers Harriman & Co. acquired a new stake in Turn Therapeutics in the 4th quarter valued at $93,000. Finally, Geode Capital Management LLC bought a new stake in Turn Therapeutics during the 4th quarter worth about $68,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.